Immune Effects

An emerging frontier: G6PD inhibition and immunotherapy

A 2024 study published in the Journal for ImmunoTherapy of Cancer added a further dimension to this landscape.

G6PD blockade was found to trigger immunogenic cell death in tumours — a form of cancer cell death that activates the immune system against the tumour — and significantly amplified the efficacy of checkpoint inhibitor immunotherapy (PD-1/PD-L1 inhibitors) in preclinical models.

This study positions G6PD inhibition not only as a direct anti-tumour and chemosensitisation strategy but potentially as an immunotherapy enhancer — a combination space of considerable current interest in oncology research.

Whether polydatin could serve this role alongside immunotherapy in humans has not yet been tested in clinical trials.

Blockade of glucose-6-phosphate dehydrogenase induces immunogenic cell death and amplifies immunotherapy response (Journal for ImmunoTherapy of Cancer, 2024)
https://jitc.bmj.com/content/12/7/e008441

See also: G6PD Inhibition